+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Alternate-day statin therapy for the treatment of hyperlipidemia



Alternate-day statin therapy for the treatment of hyperlipidemia



Annals of PharmacoTherapy 44(9): 1459-1470



To evaluate the safety, efficacy, and cost of alternate-day statin therapy in the treatment of hyperlipidemia. Systematic searches were conducted for primary literature sources involving alternative statin regimens using PubMed, EMBASE, Google Scholar, and International Pharmaceutical Abstracts (January 1966-March 2010). Articles selected were limited to those published in the English language. Reference citations from relevant publications identified were also reviewed. All English-language articles identified were reviewed and 17 trials (14 prospective and 3 retrospective) involving alternate-day statin dosing were included. Studies involving alternative statin dosing regimens other than alternating days were excluded from this review. Daily administration of statins is the standard of therapy used to reduce low-density lipoprotein cholesterol (LDL-C) levels as well as atherosclerosis that may lead to coronary events. Through LDL-C lowering and pleiotropic effects, statins decrease cardiovascular morbidity and mortality. Unfortunately, due to cost and adverse effects of statins, some patients are nonadherent to statin therapy. Several small studies have found alternate-day statin therapy to be as effective at reducing LDL-C as daily administration, while also lowering the incidence of adverse reactions and potentially lowering cost. Alternate-day statin therapy may decrease cost and therapy-limiting adverse reactions while potentially increasing regimen adherence and positively affecting the lipid panel. Further research is needed to determine whether this alternative regimen produces similar cardiovascular outcomes as those with daily statin therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 051446691

Download citation: RISBibTeXText

PMID: 20702760

DOI: 10.1345/aph.1M571


Related references

Statin therapy for hyperlipidemia. JAMA 310(11): 1185-1185, 2013

Statin-fibrate combination: therapy for hyperlipidemia: a review. Current Medical Research and Opinion 19(3): 155-168, 2003

Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia. Current Medical Research and Opinion 30(2): 223-228, 2015

Is combined statin and fibrate therapy indicated in the management of mixed hyperlipidemia?. Presse Medicale 27(15): 720-722, 1998

Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clinica Chimica Acta; International Journal of Clinical Chemistry 366(1-2): 269-273, 2005

Hyperlipidemia after renal transplantation in children on alternate day corticosteroid therapy. Clinical Nephrology 26(3): 140-145, 1986

Treatment of combined hyperlipidemia: fibrate and/or statin?. Revue Medicale de Liege 54(7): 583-587, 1999

Statin-ezetimibe combination in hyperlipidemia treatment. Casopis Lekaru Ceskych 151(1): 17-21, 2012

Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia. Minerva Cardioangiologica 46(9): 317-318, 1999

Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. Journal of Pediatrics 130(3): 470-474, 1997

Does treatment of hyperlipidemia with statin drugs reduce all-cause mortality?. Journal of the Oklahoma State Medical Association 102(5): 153-154, 2009

Treatment of hyperlipidemia with combined niacin-statin regimens. American Journal of Cardiology 82(12a): 82u-84u; Discussion 85-86u, 1999

Treatment of hyperlipidemia with combined niacin-statin regimens. American Journal of Cardiology 82(Suppl 12A): 82U-84U, Dec 17, 1998

Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology 21(12): 2026-2031, 2001